This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Mar 2011

GSK Cancels $1.5B Deal with Targacept

The two pharma companies are going in different directions with neuroscience research and this leads to their breakup.

GlaxoSmithKline has canceled its $1.5 billion dollar deal with Targacept after its decision to end all neuroscience research. The deal, first inked in 2007, covered a group of experimental NNR-targeted therapies for development of treatments for pain, smoking cessation, addiction, obesity and Parkinson's disease. Targacept gained $35 million up front and made a total of $45 million over the course of the deal.


"Our alliance with GlaxoSmithKline provided us with substantial funding at a key time

Related News